The prevalence of aspirin resistance in patients with metabolic syndrome

Turk Kardiyoloji Dernegi Arsivi

Volumn 37, Issue 7, 2009, Pages 461-466

  Çaǧirci, Göksel ^a   Özdemir, Özcan ^b   Geyik, Bilal ^b   Çay, Serkan ^c   Öztürk, Sezgin ^c   Aras, Dursun ^c   Topaloǧlu, Serkan ^c  

^a Diskapi Yildirim Beyazit Educational and Research Hospital   (Turkey)

^b Akay Hospital   (Turkey)

^c TURKIYE YUKSEK IHTISAS HOSPITAL   (Turkey)

Author keywords

Aspirin; Drug resistance metabolic syndrome X

Indexed keywords

ACETYLSALICYLIC ACID; C REACTIVE PROTEIN; GAMMA GLUTAMYLTRANSFERASE; GLUCOSE; URIC ACID;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DIET RESTRICTION; DRUG RESISTANCE; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; LOGISTIC REGRESSION ANALYSIS; MALE; METABOLIC SYNDROME X; PREVALENCE; PRIMARY PREVENTION; STATISTICAL SIGNIFICANCE; THROMBOCYTE COUNT; WAIST CIRCUMFERENCE;

AGED; ASPIRIN; BIOMARKERS, PHARMACOLOGICAL; BLOOD GLUCOSE; BLOOD PRESSURE; BODY MASS INDEX; CORONARY DISEASE; DIASTOLE; DRUG RESISTANCE; FEMALE; HUMANS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PRIMARY PREVENTION; SYSTOLE; TRIGLYCERIDES;

EID: 75649086033     PISSN: 10165169     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005;112:2735-52.
2. Eikelboom JW, Hirsh J, Weitz JI, Johnston M, Yi Q, Yusuf S. Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation 2002;105:1650-5.
3. Sanderson S, Emery J, Baglin T, Kinmonth AL. Narrative review: aspirin resistance and its clinical implications. Ann Intern Med 2005;142:370-80.
4. International Diabetes Federation. The IDF consensus worldwide definition of the metabolic syndrome. Brussels, Belgium: International Diabetes Federation; 2006. Available from: http://www.idf.org/webdata/docs/IDF-Meta-def- final.pdf.
5. Grundmann K, Jaschonek K, Kleine B, Dichgans J, Topka H. Aspirin non-responder status in patients with recurrent cerebral ischemic attacks. J Neurol 2003;250:63-6.
6. Rand ML, Leung R, Packham MA. Platelet function assays. Transfus Apher Sci 2003;28:307-17.
7. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, Ramírez C, Sabaté M, Jimenez-Quevedo P, et al. Influence of aspirin resistance on platelet function profiles in patients on long-term aspirin and Clopidogrel after percutaneous coronary intervention. Am J Cardiol 2006;97:38-43.
8. Mammen EF, Comp PC, Gosselin R, Greenberg C, Hoots WK, Kessler CM, et al. PFA-100 system: a new method for assessment of platelet dysfunction. Semin Thromb Hemost 1998;24:195-202.
9. Ford ES. Risks for all-cause mortality, cardiovascular disease, and diabetes associated with the metabolic syndrome: a summary of the evidence. Diabetes Care 2005;28:1769-78.
10. Isomaa B, Almgren P, Tuomi T, Forsén B, Lahti K, Nissén M, et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001;24:683-9.
11. Pamukçu B, Oflaz H, Nişanci Y. Aterotrombotik hastaliklarda güncel bir sorun - aspirin direnci: Tanimi, oluşum mekanizmalari, laboratuvar yöntemleri ile belirlenmesi ve klinik sonuçlari. Anadolu Kardiyol Derg 2007;7 Suppl 2:20-6.
12. Gum PA, Kottke-Marchant K, Welsh PA, White J, Topol EJ. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol 2003;41:961-5.
13. Kahraman G, Şahin T, Kiliç T, Baytugan NZ, Aǧaçdiken A, Ural E, et al. The frequency of aspirin resistance and its risk factors in patients with metabolic syndrome. Int J Cardiol 2007;115:391-6.
14. Ziegler S, Alt E, Brunner M, Speiser W, Minar E. Influence of systemic inflammation on efficiency of antiplatelet therapy in PAOD patients. Ann Hematol 2004;83:92-4.
15. Homoncik M, Blann AD, Hollenstein U, Pernerstorfer T, Eichler HG, Jilma B. Systemic inflammation increases shear stress-induced platelet plug formation measured by the PFA-100. Br J Haematol 2000;111:1250-2.
16. Poulsen TS, Mickley H. Is the antiplatelet effect of aspirin affected by systemic inflammation? Ann Hematol 2004;83:728.
17. Fateh-Moghadam S, Plöckinger U, Cabeza N, Htun P, Reuter T, Ersel S, et al. Prevalence of aspirin resistance in patients with type 2 diabetes. Acta Diabetol 2005;42:99-103.
18. Mehta SS, Silver RJ, Aaronson A, Abrahamson M, Goldfine AB. Comparison of aspirin resistance in type 1 versus type 2 diabetes mellitus. Am J Cardiol 2006;97:567-70.
19. Aktürk E, Topal E, Aksoy Y. Aspirin resistance. [Article in Turkish] Türk Kardiyol Dern Arş 2005;33:480-7.
20. Sudic D, Razmara M, Forslund M, Ji Q, Hjemdahl P, Li N. High glucose levels enhance platelet activation: involvement of multiple mechanisms. Br J Haematol 2006;133:315-22.
21. Türkoǧlu S, Abaci A. Diyabetik hastalarda aspirin. Anadolu Kardiyol Derg 2007;7 Suppl 2:5-8.
22. Keating FK, Sobel BE, Schneider DJ. Effects of increased concentrations of glucose on platelet reactivity in healthy subjects and in patients with and without diabetes mellitus. Am J Cardiol 2003;92:1362-5.
23. Vaidyula VR, Boden G, Rao AK. Platelet and monocyte activation by hyperglycemia and hyperinsulinemia in healthy subjects. Platelets 2006;17:577-85.